Who can prescribe Strattera? NP vs MD in Illinois

If you’ve been wondering whether you can start or continue ADHD treatment online—specifically with non-stimulant medications like Strattera—you’re not alone. Millions of Americans are exploring telehealth for mental health care, and ADHD treatment has become one of the most requested services. The short answer: Yes, you can get ADHD non-stimulant medication prescribed through telehealth in most cases. But there are important details about regulations, state laws, and what to expect that every patient should understand.

Understanding ADHD Non-Stimulant Medications

Before diving into the telehealth specifics, let’s clarify what we mean by ‘non-stimulant’ ADHD medication. The most common non-stimulant medication for ADHD is Strattera (atomoxetine). Unlike stimulant medications such as Adderall, Ritalin, or Vyvanse, Strattera is not a controlled substance. This distinction is crucial because it means Strattera isn’t subject to the same strict federal prescribing regulations that apply to stimulants.

Strattera works differently than stimulants—it’s a selective norepinephrine reuptake inhibitor that gradually improves ADHD symptoms over several weeks. Because it’s not habit-forming and carries no potential for abuse, the Drug Enforcement Administration (DEA) doesn’t classify it as a controlled substance. This makes prescribing it via telehealth significantly more straightforward from a regulatory standpoint.

Free consultations available with select providers only.

Get a free consultation

And find an affordable, caring specialist.

Find a provider

Free consultations available with select providers only.

Federal Telehealth Rules: What’s Allowed Right Now

The landscape of telehealth prescribing has evolved dramatically since 2020. During the COVID-19 pandemic, the DEA implemented emergency flexibilities that allowed healthcare providers to prescribe controlled substances (including ADHD stimulants) via telehealth without an initial in-person examination. These flexibilities have been extended multiple times and are currently in effect through December 31, 2025.

However, here’s the key point: These restrictions never applied to non-stimulant medications like Strattera in the first place. The Ryan Haight Act—the federal law that normally requires an in-person medical evaluation before prescribing controlled substances online—only governs controlled medications. Since Strattera isn’t controlled, licensed providers have always been able to prescribe it through telehealth, even before the pandemic.

This means that regardless of what happens with DEA rules for controlled substances in 2026, your ability to receive Strattera via telehealth should remain unchanged. The federal government doesn’t impose special telehealth restrictions on non-controlled medications.

State-by-State Telehealth Regulations

While federal law sets the baseline, individual states have their own telehealth regulations that providers must follow. The good news: no state outright bans telehealth for ADHD treatment. However, some states have implemented additional requirements or restrictions worth knowing about.

States with Minimal Restrictions

Most states, including California, Illinois, Pennsylvania, and Georgia, have embraced telehealth with few additional barriers. In these states, a licensed provider can conduct a comprehensive video evaluation, make an ADHD diagnosis, and prescribe Strattera without requiring any in-person visits. The provider simply needs to meet the same standard of care they would follow for an in-person appointment.

States with Notable Requirements

A few states have implemented specific rules you should be aware of:

Florida has specific restrictions on prescribing Schedule II stimulants via telehealth—but these don’t apply to Strattera. For non-controlled ADHD medications, Florida providers can prescribe freely via telehealth as long as they use video (not phone-only) for the consultation.

Alabama requires an in-person visit within 12 months for ongoing telehealth treatment in most cases, with an important exception: mental health services are exempt from this rule. Since ADHD is considered a psychiatric condition, ongoing telehealth ADHD care typically doesn’t trigger the 12-month in-person requirement. However, Alabama’s rules are among the strictest in the nation, so it’s worth confirming specifics with your provider.

New York implemented new rules in 2025 requiring an in-person evaluation before prescribing any controlled substance via telehealth. This affects stimulant prescriptions but not Strattera or other non-controlled ADHD medications.

New Hampshire recently updated its telehealth laws in August 2025, removing previous in-person requirements and now only mandating an annual follow-up evaluation for controlled substance prescriptions. This change significantly expanded telehealth access in the state.

Texas is generally telehealth-friendly for mental health care, with no blanket in-person requirement for ADHD treatment. However, Texas does have unique restrictions on what types of providers can prescribe certain medications (more on that below).

Who Can Prescribe ADHD Medications via Telehealth?

Not all healthcare providers have the same prescribing authority, and this varies significantly by state. Understanding who can prescribe what is important when choosing a telehealth service.

Physicians (MD/DO)

In all 50 states, licensed physicians can prescribe both stimulant and non-stimulant ADHD medications via telehealth, provided they’re licensed in your state and follow federal and state regulations. If you’re seeing a psychiatrist or primary care physician through a telehealth platform, they should have full prescribing authority for Strattera.

Nurse Practitioners and Physician Assistants

The authority of Nurse Practitioners (NPs) and Physician Assistants (PAs) to prescribe ADHD medications varies considerably by state.

For non-controlled medications like Strattera, all states allow NPs and PAs to prescribe with at least a collaborative physician agreement. Many states now grant NPs full independent practice authority, meaning they can prescribe without physician oversight after meeting certain experience requirements.

States with independent NP practice for ADHD medications include California, New York, Illinois, New Hampshire, and over 20 others. In these states, experienced NPs can evaluate you for ADHD and prescribe Strattera independently.

States requiring collaborative agreements include Florida, Texas, Pennsylvania, Alabama, and Georgia. In these states, NPs and PAs work under a supervising physician’s oversight, but they can still prescribe Strattera within the scope of their practice agreement.

It’s worth noting that restrictions tend to be tighter for stimulant (Schedule II) medications. For example, Texas prohibits NPs from prescribing Schedule II stimulants in regular outpatient settings—they can only do so in hospital or hospice care. Georgia doesn’t allow NPs to prescribe Schedule II medications at all, even with physician supervision. However, these restrictions don’t affect non-stimulant prescriptions.

When using a telehealth service like Klarity Health, the platform will match you with a provider licensed in your state with appropriate prescribing authority, so you don’t need to navigate these complexities on your own.

What to Expect from a Telehealth ADHD Evaluation

If you’re considering telehealth for ADHD treatment, it’s important to understand that legitimate providers follow the same rigorous diagnostic standards as in-person care. This isn’t a quick online quiz that automatically generates a prescription.

The Comprehensive Evaluation Process

A proper telehealth ADHD evaluation typically includes:

Detailed symptom assessment: Your provider will ask about ADHD symptoms across multiple settings (work, school, home, relationships). They’ll want to know when symptoms first appeared, how they’ve affected your functioning, and whether you’ve tried any treatments before.

Clinical interview: Expect a thorough video consultation where the provider observes your presentation, asks follow-up questions, and assesses for other conditions that might explain your symptoms or affect treatment.

Standardized rating scales: Many providers use validated ADHD assessment tools to quantify symptom severity and track improvement over time.

Medical and psychiatric history: You’ll be asked about other health conditions, medications, substance use history, and any mental health diagnoses. This information is crucial for safe prescribing.

Collateral information: Providers often request report cards, prior medical records, or input from family members to confirm that symptoms have been present since childhood and occur in multiple contexts.

Diagnostic criteria verification: Clinicians use DSM-5 criteria, which require that symptoms cause significant impairment in at least two settings and aren’t better explained by another condition.

What Disqualifies Someone from Telehealth Treatment?

Telehealth isn’t appropriate for everyone. You may not be eligible for ADHD medication via telehealth if you have:

• Uncontrolled cardiovascular conditions (high blood pressure, serious heart disease)
• History of severe mental illness requiring in-person monitoring
• Active substance use disorder
• Symptoms suggesting a medical emergency
• Suicidal ideation requiring urgent intervention
• Narrow-angle glaucoma (specific contraindication for Strattera)
• Recent MAOI antidepressant use (within 14 days)

These aren’t necessarily permanent disqualifications—they may just mean you need in-person evaluation first or additional specialty care before telehealth treatment is appropriate.

Reputable telehealth providers screen carefully for these issues. If your situation is too complex for safe remote management, a responsible provider will refer you to in-person care rather than risk prescribing inappropriately.

Why Strattera Might Be Recommended

If you’re exploring ADHD treatment options, you might wonder why a provider would suggest Strattera instead of a stimulant medication. There are several good reasons:

No abuse potential: Because Strattera isn’t a stimulant and doesn’t produce euphoria or energy boosts, it carries no risk of dependency or misuse. This makes it an excellent option if you have a personal or family history of substance abuse.

Steady symptom control: While stimulants work quickly (often within an hour), their effects also wear off after several hours. Strattera provides 24-hour symptom coverage once you reach a therapeutic dose, which some patients find more consistent.

Fewer cardiovascular concerns: Stimulants can increase heart rate and blood pressure. Strattera is often better tolerated by patients with mild cardiovascular conditions, though monitoring is still required.

Less regulatory hassle: Because Strattera isn’t controlled, you can get 90-day prescriptions with refills, rather than needing a new prescription every 30 days as required for stimulants. This means fewer appointments and pharmacy trips.

Helps with comorbid anxiety: Some patients find that Strattera also helps with anxiety symptoms, whereas stimulants can sometimes worsen anxiety.

That said, Strattera isn’t for everyone. It typically takes 4-6 weeks to reach full effectiveness, and some patients don’t respond as well as they would to stimulants. Side effects can include decreased appetite, nausea, fatigue, and in rare cases, liver problems or increased suicidal thoughts (especially in children and adolescents). Your provider will discuss whether Strattera or another medication is the best choice for your specific situation.

Prescription Monitoring and Safety Measures

Even though Strattera isn’t a controlled substance, responsible telehealth providers implement safety measures to ensure appropriate care.

Prescription Drug Monitoring Programs (PDMPs)

Most states maintain prescription drug monitoring programs that track controlled substance prescriptions. While PDMP checks aren’t legally required for Strattera (since it’s not controlled), many providers still review your prescription history as part of due diligence. This helps them see if you’re on other medications that could interact with Strattera or if there are patterns suggesting medication misuse.

States have varying PDMP requirements for controlled substances:

• Florida requires checking the PDMP before every controlled substance prescription
• California mandates checks at least every four months for ongoing controlled prescriptions
• Pennsylvania requires PDMP checks before the first prescription and every 90 days thereafter
• New Hampshire requires checking before each controlled substance prescription

These requirements primarily affect stimulant prescriptions, but knowing your provider is consulting the PDMP database demonstrates their commitment to safe prescribing practices.

Follow-Up and Monitoring

Starting Strattera requires ongoing monitoring. Expect:

Initial follow-up within 2-4 weeks to assess early response and side effects

Dose adjustments as needed—Strattera is typically started at a low dose and gradually increased

Regular check-ins every 1-3 months once you’re stable on medication

Symptom tracking using rating scales to objectively measure improvement

Vital sign monitoring—you may need to check your blood pressure and heart rate periodically

Liver function tests if you develop symptoms of liver problems (rare but serious side effect)

Quality telehealth providers like Klarity Health build these safety checks into your treatment plan, ensuring you receive comprehensive care remotely.

Recent Scrutiny and What It Means for Patients

The ADHD telehealth space has faced increased regulatory attention over the past few years. In 2022-2023, major online platforms including Cerebral and Done came under DEA investigation for allegedly over-prescribing stimulants without adequate oversight. These high-profile cases led to significant changes across the telehealth industry.

How the Industry Has Responded

Legitimate telehealth providers have implemented stricter protocols:

More thorough evaluations: Expect comprehensive diagnostic assessments, not quick questionnairesRegular follow-ups: Mandatory check-ins to monitor response and adjust treatmentTreatment agreements: Some providers now use signed agreements outlining expectations for medication useDrug screening: Periodic urine drug tests for patients on controlled substancesPrimary care coordination: Increased communication with your other healthcare providersEnhanced training: Providers receive specific training on telehealth prescribing best practices

These changes ultimately benefit patients by ensuring safer, higher-quality care. They also help protect continued telehealth access by demonstrating that remote ADHD treatment can meet rigorous clinical standards.

Red Flags to Avoid

Not all online services operate with the same level of care. Be wary of:

• Services that ‘guarantee’ you’ll get medication
• Platforms that don’t require video consultations
• Providers who prescribe after minimal questioning
• Services that don’t check your identification or medical history
• Offers to ship medication from overseas
• Providers who won’t discuss non-medication treatment options
• Services that don’t require follow-up appointments

If something seems too easy or too good to be true, it probably is. Legitimate telehealth should feel like quality healthcare—just delivered through a screen instead of in person.

What Happens Next: 2026 and Beyond

The regulatory landscape for telehealth ADHD treatment continues to evolve. Here’s what you should know about potential changes:

Federal Rule Changes

The DEA’s temporary telehealth flexibilities for controlled substances expire on December 31, 2025. A fourth extension for 2026 is under review, but it’s not yet finalized. If no new rule is in place by January 1, 2026, the original Ryan Haight Act requirements would technically resume, meaning an in-person exam would again be required before prescribing controlled substances via telehealth.

Important: This potential change would only affect stimulant medications. Your ability to receive Strattera via telehealth wouldn’t be impacted, as non-controlled medications were never subject to these restrictions.

The DEA is also considering a permanent ‘Special Registration’ framework that would create specific pathways for telehealth controlled substance prescribing with additional safeguards. A proposed rule was circulated in January 2025, but no final regulations have been adopted yet.

State-Level Trends

States are moving in various directions:

Expanding access: New Hampshire’s 2025 law removal of in-person requirements is part of a broader trend toward permanent telehealth expansion

Tightening safeguards: New York’s 2025 reinstatement of in-person exam requirements for controlled substances shows some states taking a more cautious approach

PDMP requirements: Nearly every state now mandates prescription monitoring program checks for controlled substances, and these requirements continue to expand

E-prescribing mandates: Most states now require electronic prescribing for controlled substances, reducing prescription fraud

What This Means for You

If you’re currently receiving or considering ADHD treatment via telehealth:

Stay informed: Reputable providers will notify you of any regulatory changes affecting your care

Maintain communication: Keep your follow-up appointments and stay engaged with your treatment plan

Have a backup plan: If you’re on stimulant medication and regulations change, discuss contingency plans with your provider (such as coordinating an in-person visit if needed)

Don’t panic: The telehealth industry and advocates are working to ensure continuity of care for established patients

For Strattera and other non-controlled ADHD medications, the regulatory outlook remains stable. The current accessibility of non-stimulant ADHD treatment via telehealth is unlikely to change regardless of how controlled substance rules evolve.

How Klarity Health Makes ADHD Treatment Accessible

Navigating the complexities of telehealth ADHD treatment can feel overwhelming, but services like Klarity Health are designed to make the process straightforward and compliant with all regulations.

Klarity matches you with licensed providers—psychiatrists, psychiatric nurse practitioners, or physician assistants—who are credentialed in your state and have appropriate prescribing authority. The platform ensures that your provider follows all federal and state telehealth regulations, including DEA requirements when applicable.

What sets quality telehealth services apart:

Comprehensive evaluations: Thorough diagnostic assessments using evidence-based criteriaProvider availability: Access to care without lengthy wait times typical of traditional psychiatryTransparent pricing: Clear information about costs, with options for both insurance and self-payInsurance acceptance: Working with major insurance plans to make care affordableFlexible scheduling: Appointments that fit your schedule, including evenings and weekendsCoordinated care: Communication with your other healthcare providers when appropriateOngoing support: Regular follow-ups and medication management, not just one-time prescriptions

For non-stimulant ADHD medications like Strattera, Klarity’s providers can typically start treatment after your initial evaluation if appropriate for your situation. The platform handles all the regulatory compliance, prescription transmission to your pharmacy, and scheduling of follow-up appointments.

Taking the Next Step

If you’re struggling with ADHD symptoms and wondering whether telehealth treatment is right for you, here’s how to move forward:

1. Reflect on your symptoms: Consider how ADHD symptoms are affecting your work, relationships, and daily functioning. Be prepared to discuss specific examples.

2. Gather information: Collect any previous medical records, prior ADHD evaluations, report cards from school, or other documentation that might be helpful.

3. Check your eligibility: Make sure you don’t have acute medical or psychiatric issues requiring in-person evaluation.

4. Choose a reputable provider: Look for established telehealth services with licensed clinicians, clear policies, and proper credentials.

5. Be thorough and honest: Provide complete information during your evaluation—the quality of your care depends on it.

6. Commit to the process: Understand that ADHD treatment is ongoing. Whether you start on Strattera or another medication, you’ll need regular follow-ups and potentially dose adjustments.

7. Stay engaged: Attend appointments, communicate about side effects or concerns, and be an active participant in your treatment.

Telehealth has transformed access to ADHD care, making it possible to receive quality treatment without the barriers of long wait times, transportation issues, or scheduling inflexibility. For non-stimulant medications like Strattera, the regulatory pathway is clear and stable, giving you confidence that you can access care remotely both now and in the future.

Frequently Asked Questions

Is a telehealth ADHD diagnosis as valid as an in-person diagnosis?

Yes. When conducted properly by a licensed clinician using video consultation and following DSM-5 criteria, a telehealth ADHD diagnosis is just as valid as an in-person evaluation. The key is ensuring your provider conducts a comprehensive assessment rather than relying on a brief questionnaire.

Will my pharmacy fill a prescription from a telehealth provider?

In almost all cases, yes. Electronic prescriptions are standard whether your visit was telehealth or in-person, and pharmacies routinely fill prescriptions from licensed telehealth providers. For non-controlled medications like Strattera, there’s typically no additional scrutiny.

Can I use telehealth if I’ve never been diagnosed with ADHD before?

Absolutely. Many patients receive their initial ADHD diagnosis through telehealth. The provider will conduct a thorough evaluation to determine whether your symptoms meet diagnostic criteria.

What if I want to try a stimulant medication instead of Strattera?

Your provider will discuss all appropriate treatment options with you. If a stimulant medication is clinically indicated and you don’t have contraindications, providers can prescribe these via telehealth under current federal rules (through December 31, 2025, with anticipated extensions).

How much does telehealth ADHD treatment cost?

Costs vary depending on whether you use insurance or self-pay, and which provider you see. Many telehealth platforms offer transparent pricing—for example, initial consultations might range from $99-$299 for self-pay, with follow-ups typically $99 or less. Insurance co-pays depend on your specific plan. Klarity Health accepts both insurance and self-pay, providing flexibility based on your situation.

What if I move to a different state?

Healthcare providers must be licensed in the state where you’re located at the time of treatment. If you move, you’ll need to either find a new provider licensed in your new state, or check whether your current provider also holds a license there. Many telehealth providers are licensed in multiple states, but this varies.

Telehealth has made ADHD treatment more accessible than ever before, particularly for non-stimulant medications like Strattera that aren’t subject to controlled substance restrictions. By understanding the regulatory landscape, choosing reputable providers, and staying engaged in your treatment, you can receive high-quality ADHD care from the comfort of your home. The key is finding a provider who combines clinical excellence with regulatory compliance—ensuring you receive safe, effective treatment that meets all legal requirements.

If you’re ready to explore whether telehealth ADHD treatment is right for you, consider starting with a comprehensive evaluation through a trusted platform like Klarity Health, where experienced providers can assess your symptoms, discuss treatment options, and create a personalized care plan that fits your needs and circumstances.

References

1. Fierce Healthcare. (2024, November). ‘DEA finalizes one-year extension of controlled substance prescribing via telehealth.’ Retrieved from www.fiercehealthcare.com

2. McDermott Will & Emery LLP. (2025). ‘DEA signals extension of telemedicine flexibilities for controlled substance prescribing for 2026.’ Retrieved from www.mwe.com

3. Sheppard Mullin Healthcare Law Blog (National Law Review). (2025, August 15). ‘Telehealth and in-person visits: Tracking federal and state updates to pandemic-era telehealth exceptions.’ Retrieved from www.sheppardhealthlaw.com

4. RxAgent. (2025, October). ‘The Telehealth Compliance Trap: Why Your State Might Not Let You Skip That Office Visit.’ Retrieved from www.rxagent.co

5. Medical News Today. (2025, January 14). ‘Is Strattera a controlled substance?’ Retrieved from www.medicalnewstoday.com

Note: Regulatory information verified as of December 17, 2025. DEA pandemic-era telehealth prescribing flexibilities for controlled substances (Schedules II-V) are extended through December 31, 2025. State-specific information confirmed via 2025 sources for CA, NY, FL, TX, AL, NH, and GA. Patients should verify current regulations with their provider as rules continue to evolve.

Source:

• https://www.fiercehealthcare.com/regulatory/dea-finalizes-one-year-extension-controlled-substance-prescribing-telehealth-punts-final#:~:text=The%20Drug%20Enforcement%20Administration%20,Federal%20Register%20on%20Friday%20night
• https://www.mwe.com/insights/dea-signals-extension-of-telemedicine-flexibilities-for-controlled-substance-prescribing-for-2026/#:~:text=visit,examination%20through%20December%2031%2C%202025
• https://www.mwe.com/insights/dea-signals-extension-of-telemedicine-flexibilities-for-controlled-substance-prescribing-for-2026/#:~:text=A%20new%20rule%20posted%20on,date%20of%20December%2031%2C%202025
• https://www.fiercehealthcare.com/regulatory/dea-finalizes-one-year-extension-controlled-substance-prescribing-telehealth-punts-final#:~:text=The%20%E2%80%9CThird%20Temporary%20Extension%20of,14
• https://www.medicalnewstoday.com/articles/drugs-is-strattera-a-controlled-substance#:~:text=Strattera%20,such%20as%20mental%20health%20issues
• https://www.sheppardhealthlaw.com/2025/08/articles/telehealth/telehealth-and-in-person-visits-tracking-federal-and-state-updates-to-pandemic-era-telehealth-exceptions/#:~:text=In%20late%202024%2C%20the%20U,prescribing
• https://www.rxagent.co/blog/telehealth-compliance-trap#:~:text=The%20,False%20Hope
• https://www.techtarget.com/virtualhealthcare/news/366616019/Telehealth-prescribing-flexibility-extended-through-2025#:~:text=Image%20filo%2FDigitalVision%20Vectors%20via%20G,The
• https://natlawreview.com/article/telehealth-and-person-visits-tracking-federal-and-state-updates-pandemic-era?amp=#:~:text=Extend%20natlawreview,before%20issuing%20a%20dangerous%20drug
• https://www.rxagent.co/blog/telehealth-compliance-trap#:~:text=,specifically%20for%20chronic%20pain%20treatment